Item 8.01 Other Events.
On January 19, 2022, VYNE Therapeutics Inc. (the "Company") issued a press
release entitled "VYNE Therapeutics Announces Phase 1b Data for FMX114 from
Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis." A
copy of the press release is attached as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated by reference herein.
In addition, the Company updated its investor presentation to include a slide
(slide 13) detailing the Phase 1b data. The updated investor presentation can be
found in the "Events & Presentations" section of the Company's website,
Item 9.01. Financial Statements and Exhibits.
The following exhibit is being filed herewith.
Exhibit No. Description
99.1 Press Release, dated January 19, 2022.
Cover Page Interactive Data File (embedded within the Inline XBRL
© Edgar Online, source Glimpses